Computational chemistry

PsiQuantum, Mitsubishi UFJ Financial Group and Mitsubishi Chemical Announce Partnership to Design Energy-Efficient Materials on PsiQuantum’s Fault-Tolerant Quantum Computer

Retrieved on: 
Wednesday, January 24, 2024
Semiconductor, Chemicals, Plastics, Technology, Manufacturing, Other Manufacturing, Hardware, Mitsubishi UFJ Financial Group, Physics, Mitsubishi Chemical Corporation, Chemistry, Partnership, Density functional theory, Density, DFT, Climate, Computational chemistry, MUFG, Mitsubishi Group

Mitsubishi UFJ Financial Group (MUFG) is committed to supporting the world’s transition to a sustainable future, and to encourage industry access to the most promising breakthrough technologies.

Key Points: 
  • Mitsubishi UFJ Financial Group (MUFG) is committed to supporting the world’s transition to a sustainable future, and to encourage industry access to the most promising breakthrough technologies.
  • By pioneering PsiQuantum’s Qlimate solutions with industry leader Mitsubishi Chemical, MUFG is at the forefront of quantum computing for sustainability.
  • The project will allow Mitsubishi Chemical to gain early insights into how and when fault-tolerant quantum computing can be deployed in support of critical, scalable, sustainable materials.
  • We hope the partnership will accelerate the innovation of revolutionizing computational studies in chemistry and materials science.”

Svante Charts the Course to a Greener Future, Fueling Innovation with Rescale

Retrieved on: 
Wednesday, January 17, 2024
CO2, FEA, Carbon, Climate change, Computational chemistry, DAC, Research, HPC, Renewable energy

"Working with Rescale has assisted in accelerating our innovation and bringing our vision for a sustainable future closer to reality."

Key Points: 
  • "Working with Rescale has assisted in accelerating our innovation and bringing our vision for a sustainable future closer to reality."
  • "We are proud to support Svante in its mission to combat climate change," said Joris Poort, CEO of Rescale.
  • From the stage in Davos, Svante and Rescale extend a call to action to businesses and global leaders.
  • Svante, with the power of the Rescale platform and other solutions, is paving the way for a greener future, and invites everyone to join the journey.

Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

Retrieved on: 
Tuesday, January 16, 2024
JPMorgan Chase, Amgen, Research, Mitsui & Co., Airbus, AI, HSBC, Carbon, Digital, Transport, Cambridge Quantum Computing, Organization, Computational chemistry, BMW, Cryptocurrency

CHARLOTTE, N.C., Jan. 16, 2024 /PRNewswire/ -- Honeywell (NASDAQ: HON) today announced the closing of a $300 million equity fundraise for Quantinuum, the world's leading integrated quantum computing company, at a pre-money valuation of $5 billion. The round is anchored by Quantinuum's strategic partner JPMorgan Chase, with additional participation from Mitsui & Co., Amgen and Honeywell, which remains the company's majority shareholder. This investment brings the total capital raised by Quantinuum since inception to approximately $625 million.

Key Points: 
  • CHARLOTTE, N.C., Jan. 16, 2024 /PRNewswire/ -- Honeywell (NASDAQ: HON) today announced the closing of a $300 million equity fundraise for Quantinuum, the world's leading integrated quantum computing company, at a pre-money valuation of $5 billion.
  • The round is anchored by Quantinuum's strategic partner JPMorgan Chase, with additional participation from Mitsui & Co., Amgen and Honeywell, which remains the company's majority shareholder.
  • This investment brings the total capital raised by Quantinuum since inception to approximately $625 million.
  • This capital raise represents Quantinuum's first equity funding round since Cambridge Quantum Computing and Honeywell Quantum Solutions merged in November 2021.

Advent Technologies Announces Appointment of Naiem Hussain as Chief Financial Officer

Retrieved on: 
Thursday, January 11, 2024
Environment, Technology, Engineering, Manufacturing, Alternative Energy, Sustainability, Green Technology, Energy, Batteries, Intelligent Energy, ICI, Specialization, Green, ADN, CFO, Fellow, Close Brothers Group, University of Oxford, Initial public offering, Johnson Matthey, Imperial College Innovations, Computational chemistry, Investment, AstraZeneca, Anglo American Platinum, Naim

Advent Technologies Holdings, Inc. (NASDAQ: ADN), an innovation-driven leader in the fuel cell and hydrogen technology space, announced today the appointment of Naiem Hussain as its new Chief Financial Officer pending the completion of the company’s hiring protocols.

Key Points: 
  • Advent Technologies Holdings, Inc. (NASDAQ: ADN), an innovation-driven leader in the fuel cell and hydrogen technology space, announced today the appointment of Naiem Hussain as its new Chief Financial Officer pending the completion of the company’s hiring protocols.
  • Formerly serving as Advent’s Chief Investment Officer, Mr. Hussain brings extensive expertise in corporate finance, with a focus on IPOs, fundraisings, and mergers and acquisitions within the energy technology and fuel cell industries.
  • Mr. Hussain is replacing Kevin Brackman, who resigned from his position on January 5, 2024.
  • In response to his appointment, Mr. Hussain stated, "I am thrilled to take on the role of CFO at Advent during this crucial phase for the Company.

SandboxAQ Acquires Good Chemistry to Accelerate AI Simulation Platform for Drug Discovery and Material Science

Retrieved on: 
Tuesday, January 9, 2024
Cloud, Allianz, Head, Dow, SDK, GitHub, Chemistry, Software as a service, PALO, Drug discovery, Acquisition, Quantum, Fujitsu, Computational chemistry, Medical device

PALO ALTO, Calif. and VANCOUVER, BC, Jan. 9, 2024 /PRNewswire/ -- SandboxAQ today announced it has acquired Good Chemistry, a leading computational chemistry company that leverages AI, quantum and other advanced technologies to accelerate drug discovery and materials design. Terms of the acquisition were not disclosed.

Key Points: 
  • PALO ALTO, Calif. and VANCOUVER, BC, Jan. 9, 2024 /PRNewswire/ -- SandboxAQ today announced it has acquired Good Chemistry , a leading computational chemistry company that leverages AI, quantum and other advanced technologies to accelerate drug discovery and materials design.
  • Good Chemistry, which spun out of 1Qbit in 2021, is SandboxAQ's second acquisition and its first in the AI simulation sector.
  • Good Chemistry founder and CEO Arman Zaribafiyan will join SandboxAQ as Head of Product for AI Simulation Platforms.
  • The company's computational and quantum chemists, AI software developers, machine-learning engineers, and quantum computing scientists will join the existing SandboxAQ simulation teams.

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor

Retrieved on: 
Wednesday, January 3, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Machine learning, Physics, Pain scale, Pharmacokinetics, Computational chemistry, Patient, Safety, Therapy, Inflammation, Pharmaceutical industry

Ventus Therapeutics , a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVETM, to develop differentiated small molecule therapeutics, announced today that the first participant has been dosed in a Phase 1 clinical trial of VENT-03, the first cGAS inhibitor to advance into clinical development.

Key Points: 
  • Ventus Therapeutics , a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVETM, to develop differentiated small molecule therapeutics, announced today that the first participant has been dosed in a Phase 1 clinical trial of VENT-03, the first cGAS inhibitor to advance into clinical development.
  • “cGAS has historically proven an elusive target despite significant industry efforts to develop a viable inhibitor.
  • We have broken that cycle with the initiation of this Phase 1 clinical trial,” said Ventus President and CEO Marcelo Bigal, M.D., Ph.D. “We are eager to advance this therapeutic candidate and bring the potential of cGAS inhibition to patients suffering from inflammatory disorders with significant unmet needs.
  • Ventus expects results from the trial in the second half of 2024.

Cadence Partners with Antiviral Discovery Consortium to Spearhead Rapid Development of Treatments for Viral Pandemics

Retrieved on: 
Thursday, December 7, 2023
Technology, Clinical Trials, Health Technology, Software, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, ACT, Diamond, Pandemic, Computational chemistry, Trust, ASAP, COVID Moonshot, Weizmann Institute of Science, OpenEye Scientific Software, Drug, Moonshot, Environmental Molecular Sciences Laboratory, Artificial intelligence, Protogygia postera, Diamond Light Source, Machine learning, Therapy, NIH, Drug discovery, Human, OMEGA, Wellcome, Doctor of Philosophy, Pi, Orion, MSKCC, Cadence Design Systems, Pharmaceutical industry

Cadence Molecular Sciences (OpenEye)—a business unit of Cadence Design Systems (Nasdaq: CDNS)—will provide OpenEye’s molecular design software to power the open-science AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium in support of an innovative effort to rapidly develop antivirals to prevent future pandemics.

Key Points: 
  • Cadence Molecular Sciences (OpenEye)—a business unit of Cadence Design Systems (Nasdaq: CDNS)—will provide OpenEye’s molecular design software to power the open-science AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium in support of an innovative effort to rapidly develop antivirals to prevent future pandemics.
  • Chodera and the ASAP scientists working with him will have access to OpenEye tools to help support the ASAP Discovery Consortium and antiviral drug research,” said Anthony Nicholls, PhD, corporate vice president, OpenEye, Cadence Molecular Sciences.
  • “Open-science drug discovery against future pandemics is an essential public service,” said Chodera.
  • The ASAP Discovery Consortium is led by PIs John Chodera (MSKCC), Alpha Lee (PostEra) and Peter Sjö (DNDi).

InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical Executive, Mark Levick, MD, Ph.D. as New Board Director

Retrieved on: 
Tuesday, October 3, 2023
Research, Technology, Genetics, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Faculty, GSK, Royal college, University, Drug development, Senior, Tropical medicine, G protein-coupled receptor, Levick, University of Cambridge, Membership of the Royal College of Physicians of Ireland, Cancer, ETH Zurich, Faculty of Pharmaceutical Medicine, Multimedia, Biomarker, Computational chemistry, Doctor of Philosophy, Language, Paul Scherrer Institute, GPCR, Novartis, MD, Vivo, Drug discovery, Commonwealth Scholarship and Fellowship Plan, Artificial intelligence, Marie Cassidy, FRCPA, University of Newcastle, Pharmaceutical medicine, Pharmacology, Medical device, Pharmaceutical industry, EU, Physician, AI

InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors.

Key Points: 
  • InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20231003682932/en/
    Dr. Mark Levick, MD, Newly appointed Board Director of InterAx Biotech (Photo: Business Wire)
    Mark Levick is the former CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ.
  • In addition to building the company’s pipeline, Mark and his team led the approval and commercial launch of Simlandi/Hukyndra in 17 countries.
  • Mark has received several awards and authored peer-reviewed papers in the fields of tropical medicine, vaccine immunology and drug development.

Sepion Technologies Opens One of Largest Separator Coating Facilities for Lithium-Metal Batteries in North America

Retrieved on: 
Tuesday, September 26, 2023
Automotive Manufacturing, EV, Electric Vehicles, Automotive, Technology, Manufacturing, Batteries, Other Manufacturing, Green Technology, Environment, Sustainability, Chemicals, Plastics, Ghostbusters, Original equipment manufacturer, Vehicle registration plates of Nepal, EVS, Operation, Entrepreneurship, Graphite, LMB, Fortune 500, Computational chemistry, Machine learning, Renewable energy, Electric battery

Sepion Technologies, a leading battery product company focused on advancing lithium-metal batteries (LMBs) for electric vehicles (EVs) and e-mobility applications, announces the opening of one of North America's largest separator coating facilities for LMBs.

Key Points: 
  • Sepion Technologies, a leading battery product company focused on advancing lithium-metal batteries (LMBs) for electric vehicles (EVs) and e-mobility applications, announces the opening of one of North America's largest separator coating facilities for LMBs.
  • This cutting-edge, 100 percent renewable-energy-powered building spans 25,000 square feet, increasing Sepion's separator coating capacity by 1,000-fold and polymer synthesis scale by 100-fold.
  • These enhancements will expedite the transition of Sepion's LMB separator coatings from prototype to pilot-scale production in collaboration with leading automotive OEMs.
  • Sepion is actively developing separator products and sampling with Fortune 100 automotive companies and global battery suppliers.

TANAKA Memorial Foundation to Offer Precious Metals Research Grants of Up to 10 Million Yen (from a Grant Pool of 20 Million Yen) - Applications for Research Projects Open on September 4

Retrieved on: 
Monday, September 4, 2023
Asian Young Researchers Conference on Computational and Omics Biology, Ruthenium, Rudolf Mössbauer, University, Silver, Osmium, Platinum, Mon, Research, Computational chemistry, Orientation, Palladium, Newsfirst Platinum Awards, Science, Gold, Gold Awards, Iridium, Rhodium, Pharmaceutical industry, Nursing

Applications for the grants are open to Japanese educational institutions and public research institutes conducting research and development that will bring about innovative evolution in new research and development, and product development, in the area of precious metals.

Key Points: 
  • Applications for the grants are open to Japanese educational institutions and public research institutes conducting research and development that will bring about innovative evolution in new research and development, and product development, in the area of precious metals.
  • In this 25th year of the research grant, recipients will receive a total of 20 million yen in research grants, including the new Umekichi Tanaka Award of 10 million yen, which is the maximum amount offered.
  • Named after company founder Umekichi Tanaka, who strove to expand industrial use of precious metals, the Umekichi Tanaka Award is offered this year to commemorate the 25th anniversary of these Precious Metals Research Grants.
  • Names of the other awards were also changed with the aim of making the grant program more appealing.